Search

Your search keyword '"Yves Humblet"' showing total 3 results
Start Over Author "Yves Humblet" Journal british journal of cancer
3 results on '"Yves Humblet"'

1. Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone

Author

Catherine Hubert, Javier Carrasco, M. Van den Eynde, Anne Jouret-Mourin, J-L Canon, Etienne Danse, J-F Gigot, B. Navez, X Chapaux, Marco Gizzi, Christine Sempoux, Géraldine Pairet, P. Lefesvre, Yves Humblet, N Tinton, and Valérie Lannoy

Subjects
Oncology, Adult, Male, Cancer Research, medicine.medical_specialty, Disease free survival, Organoplatinum Compounds, Angiogenesis, Colorectal cancer, medicine.medical_treatment, colorectal cancer, Antineoplastic Agents, Irinotecan, Disease-Free Survival, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Pathological, EGFR inhibitors, Aged, Retrospective Studies, Aged, 80 and over, Chemotherapy, Neovascularization, Pathologic, business.industry, Retrospective cohort study, surgical resection, Middle Aged, medicine.disease, targeted therapy, ErbB Receptors, Oxaliplatin, Camptothecin, Female, business, Translational Therapeutics, Colorectal Neoplasms, pathological response, liver metastases, medicine.drug
Abstract

Background: Optimal preoperative treatment before colorectal cancer metastases (CRCM) resection remains unclear. This study evaluated pathological responses (pR) in CRCM resected after chemotherapy alone or combined with angiogenesis or epidermal growth factor receptor (EGFR) inhibitors. Methods: Pathological response was retrospectively evaluated on 264 resected metastases from 99 patients. The proportion of responding metastases after different preoperative treatments was reported and compared. Patient's progression-free survival (PFS) and overall survival (OS) were compared based on pR. Results: The combination of anti-angiogenics with oxaliplatin-based chemotherapy resulted in more pR than when they were combined with irinotecan-based chemotherapy (80% vs 50% P

Published
2015

2. Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab

Author

Emilio Bajetta, D Comandini, R Amado, Salvatore Siena, T. Salek, M Woolley, G. Van Hazel, Pierfranco Conte, Yves Humblet, E. Van Cutsem, Marc Peeters, G Devercelli, Michael Wolf, György Bodoky, UCL - MD/MINT - Département de médecine interne, and UCL - (SLuc) Unité d'oncologie médicale

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Colorectal cancer, Severity of Illness Index, Drug Administration Schedule, law.invention, disease progression, Quality of life, Randomized controlled trial, law, Internal medicine, Clinical Studies, Severity of illness, medicine, Humans, Panitumumab, Progression-free survival, Neoplasm Metastasis, improvement, Survival analysis, progression free survival, Colorectal Neoplasms - drug therapy, pathology, business.industry, Antibodies, Monoclonal - immunology, therapeutic use, Antibodies, Monoclonal, medicine.disease, symptom, Survival Analysis, Surgery, ErbB Receptors, patient reported outcome, Treatment Outcome, quality of life, patient-reported outcomes, panitumumab, Drug Resistance, Neoplasm, Disease Progression, Quality of Life, Self-Examination, Receptor, Epidermal Growth Factor, Colorectal Neoplasms, business, Progressive disease, medicine.drug
Abstract

In a randomised phase 3 trial, panitumumab significantly improved progression-free survival (PFS) in patients with refractory metastatic colorectal cancer (mCRC). This analysis characterises the association of PFS with CRC symptoms, health-related quality of life (HRQoL), and overall survival (OS). CRC symptoms (NCCN/FACT CRC symptom index, FCSI) and HRQoL (EQ-5D) were assessed for 207 panitumumab patients and 184 best supportive care (BSC) patients who had at least one post-baseline patient-reported outcome (PRO) assessment. Patients alive at week 8 were included in the PRO and OS analyses and categorised by their week 8 progression status as follows: no progressive disease (no PD; best response of at least stable disease) vs progressive disease (PD). Standard imputation methods were used to assign missing values. Significantly more patients were progression free at weeks 8–24 with panitumumab vs BSC. After excluding responders, a significant difference in PFS remained favouring panitumumab (HR=0.63, 95% CI=0.52–0.77; P

Published
2007
Full Text
View/download PDF

3. Tallimustine in advanced previously untreated colorectal cancer, a phase II study

Author

I. Corradino, Yves Humblet, C.J.A. Punt, A. Polli, Elisa Roca, R. Wainstein, Luc Dirix, and Other departments

Subjects
Adult, Male, Cancer Research, Pathology, medicine.medical_specialty, Myeloid, Lymphoma, Colorectal cancer, Microgram, medicine.medical_treatment, Phases of clinical research, Antineoplastic Agents, Neutropenia, Gastroenterology, Drug Administration Schedule, Experimental diagnostics and therapy of malignancies, Internal medicine, medicine, Humans, GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries), Aged, Chemotherapy, Blood Cells, Leukemia, business.industry, Distamycins, Tallimustine, Bacterial Infections, Middle Aged, medicine.disease, Combined Modality Therapy, Magnetic Resonance Imaging, medicine.anatomical_structure, Oncology, Mycoses, Toxicity, Nitrogen Mustard Compounds, Female, business, Colorectal Neoplasms, Infection, Research Article
Abstract

Tallimustine is a novel benzoyl mustard derivative from distamycin A with a unique mode of action. It is a DNA minor groove binder and produces highly sequence-specific alkylations. Previous studies have shown significant anti-tumour effects in animal models. We performed a phase II study in previously untreated patients with advanced colorectal cancer, using a schedule of i.v. bolus infusions of 900 microgram m-2 once every 4 weeks. Seventeen patients were enrolled, and no responses were documented in 14 evaluable patients. Toxicity mainly consisted a highly selective neutropenia, which warrants further investigation of this agent in combination with myeloid growth factors.

Published
1996

Catalog

Books, media, physical & digital resources
See catalog results